Pfizer (NYSE:PFE) Announces Quarterly Earnings Results

05 May 2026, 13:32 by Jessica Moore · The Cerbat Gem

Pfizer (NYSE:PFE – Get Free Report) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04, FiscalAI reports. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period last year, the firm earned $0.92 EPS. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer updated its FY 2026 guidance to 2.800-3.000 EPS.

Here are the key takeaways from Pfizer’s conference call:

Pfizer exceeded Q1 expectations with $14.5B in revenues and $0.75 adjusted EPS, and management is reaffirming full‑year 2026 guidance of $59.5B–$62.5B revenue and $2.80–$3.00 adjusted EPS.
Two legal wins — a settlement extending exclusivity on VYNDAQEL and a favorable Belgium ruling on Comirnaty EU contracts — improve post‑2028 cash flow visibility and underpin management’s expectation of a high single‑digit five‑year revenue CAGR beginning in 2029.
Management highlighted strong commercial and R&D momentum: launched/acquired products grew ~22% in Q1, oncology assets (PADCEV, ELREXFIO) and atirmociclib reported encouraging data, and Pfizer plans ~20 pivotal starts plus 10 obesity Phase IIIs targeting first approvals in 2028.
Near‑term risks persist — multiple upcoming loss‑of‑exclusivity events, seasonally back‑loaded COVID vaccine/PAXLOVID demand, and leverage around 2.8x — which management says may limit large share repurchases despite ~$7B BD capacity after ViiV proceeds.

Pfizer Trading Down 0.7%

Shares of PFE stock traded down $0.20 during mid-day trading on Tuesday, reaching $26.11. The stock had a trading volume of 28,354,259 shares, compared to its average volume of 42,573,512. The stock’s 50-day moving average price is $27.17 and its two-hundred day moving average price is $26.11. Pfizer has a 52-week low of $21.97 and a 52-week high of $28.75. The firm has a market capitalization of $148.44 billion, a PE ratio of 19.16 and a beta of 0.35. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. Pfizer’s payout ratio is presently 126.47%.

Analyst Ratings Changes

PFE has been the subject of a number of research analyst reports. Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. CICC Research initiated coverage on shares of Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective for the company. Guggenheim lifted their price objective on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. HSBC lifted their price objective on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $30.00 target price on shares of Pfizer in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $28.74.

Check Out Our Latest Stock Analysis on PFE

Hedge Funds Weigh In On Pfizer

A number of hedge funds have recently modified their holdings of the company. State Street Corp increased its position in shares of Pfizer by 0.9% during the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after buying an additional 2,786,098 shares during the period. Morgan Stanley increased its position in shares of Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after buying an additional 14,342,946 shares during the period. Northern Trust Corp increased its position in shares of Pfizer by 1.4% during the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after buying an additional 869,175 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Pfizer by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 50,540,119 shares of the biopharmaceutical company’s stock valued at $1,258,449,000 after buying an additional 410,082 shares during the period. Finally, Amundi increased its position in shares of Pfizer by 13.4% during the fourth quarter. Amundi now owns 47,063,380 shares of the biopharmaceutical company’s stock valued at $1,171,879,000 after buying an additional 5,572,451 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Q1 results topped estimates — Pfizer reported $0.75 EPS (vs. $0.71 consensus) and $14.45B revenue, driven by stronger sales of Eliquis and cancer treatments, showing underlying commercial momentum. Pfizer (PFE) Q1 Earnings and Revenues Top Estimates
Positive Sentiment: Company press release and deck reaffirm full‑year 2026 outlook while highlighting pipeline progress and recent M&A (obesity/other assets) that support medium‑term growth. Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance (Press Release)
Positive Sentiment: Major outlets note the beat and attribute strength to non‑COVID portfolio diversification (Eliquis and recent acquisitions), a narrative that supports confidence in near‑term revenue stability. Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis
Neutral Sentiment: Technical/market context: analysts and technicians are watching chart trendlines after earnings — short‑term technicals may add volatility independent of fundamentals. 2 Trendlines in Focus For Pfizer Stock After Earnings
Negative Sentiment: Guidance and outlook nuance — FY‑2026 EPS guidance was set at $2.80–$3.00 and revenue at $59.5B–$62.5B, roughly in line but slightly below some consensus points; that tempered the upside from the quarter. PFE Earnings: Pfizer Stock Rises on Q1 Beat despite Lower 2026 Sales Outlook
Negative Sentiment: Higher R&D spending weighed on profit margins — the company noted increased R&D outlays, which reduced net profit despite revenue growth. That raises near‑term margin pressure and investor concern about spend vs. timing of returns. Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending
Negative Sentiment: Valuation/yield caution — some commentary highlights that the stock’s high dividend yield and long‑term price performance prompt income investors to question growth prospects (sentiment that can pressure the share price if concerns persist). Pfizer Stock: Still Priced Like It’s Dead Money

About Pfizer

(Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.